Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID-19 Impact on General Anesthesia Drugs Market 

5.1. COVID-19 Landscape: General Anesthesia Drugs Industry Impact

5.2. COVID-19  Impact Assessment for the Industry

5.3. COVID-19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global General Anesthesia Drugs Market, By Drug

8.1. General Anesthesia Drugs Market Revenue and Volume Forecast, by Drug, 2024-2032

8.1.1. Sevoflurane

8.1.1.1. Market Revenue and Volume Forecast (2023-2032)

8.1.2. Propofol

8.1.2.1. Market Revenue and Volume Forecast (2023-2032)

8.1.3. Dexmedetomidine

8.1.3.1. Market Revenue and Volume Forecast (2023-2032)

8.1.4. Remifentanil

8.1.4.1. Market Revenue and Volume Forecast (2023-2032)

8.1.5. Desflurane

8.1.5.1. Market Revenue and Volume Forecast (2023-2032)

8.1.6. Midazolam

8.1.6.1. Market Revenue and Volume Forecast (2023-2032)

8.1.7. Others - (Sufentanil, Fentanyl, Ketamine, Isoflurane, Thiopental, Etc.)

8.1.7.1. Market Revenue and Volume Forecast (2023-2032)

Chapter 9. Global General Anesthesia Drugs Market, By Route of Administration

9.1. General Anesthesia Drugs Market Revenue and Volume Forecast, by Route of Administration, 2024-2032

9.1.1. Intravenous

9.1.1.1. Market Revenue and Volume Forecast (2023-2032)

9.1.2. Inhaled

9.1.2.1. Market Revenue and Volume Forecast (2023-2032)

Chapter 10. Global General Anesthesia Drugs Market, By Application

10.1. General Anesthesia Drugs Market Revenue and Volume Forecast, by Application, 2024-2032

10.1.1. Heart Surgeries

10.1.1.1. Market Revenue and Volume Forecast (2023-2032)

10.1.2. Cancer

10.1.2.1. Market Revenue and Volume Forecast (2023-2032)

10.1.3. General Surgery

10.1.3.1. Market Revenue and Volume Forecast (2023-2032)

10.1.4. Knee and Hip Replacements

10.1.4.1. Market Revenue and Volume Forecast (2023-2032)

10.1.5. Others

10.1.5.1. Market Revenue and Volume Forecast (2023-2032)

Chapter 11. Global General Anesthesia Drugs Market, By End-use 

11.1. General Anesthesia Drugs Market Revenue and Volume Forecast, by End-use, 2024-2032

11.1.1. Hospitals

11.1.1.1. Market Revenue and Volume Forecast (2023-2032)

11.1.2. Ambulatory Surgical Centers

11.1.2.1. Market Revenue and Volume Forecast (2023-2032)

11.1.3. Others

11.1.3.1. Market Revenue and Volume Forecast (2023-2032)

11.1.4. Cervical

11.1.4.1. Market Revenue and Volume Forecast (2023-2032)

11.1.5. Malignant

11.1.5.1. Market Revenue and Volume Forecast (2023-2032)

Chapter 12. Global General Anesthesia Drugs Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.1.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.1.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.1.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.1.5.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.1.5.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.1.5.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.1.6.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.1.6.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.1.6.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.2.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.2.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.2.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.2.5.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.2.5.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.2.5.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.2.6.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.2.6.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.2.7.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.2.7.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.2.7.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.2.8.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.2.8.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.2.8.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.3.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.3.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.3.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.3.5.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.3.5.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.3.5.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.3.6.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.3.6.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.3.7.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.3.7.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.3.7.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.3.8.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.3.8.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.3.8.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.4.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.4.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.4.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.4.5.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.4.5.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.4.5.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.4.6.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.4.6.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.4.7.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.4.7.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.4.7.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.4.8.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.4.8.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.4.8.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.5.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.5.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.5.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.5.5.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.5.5.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.5.5.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Drug (2023-2032)

12.5.6.2. Market Revenue and Volume Forecast, by Route of Administration (2023-2032)

12.5.6.3. Market Revenue and Volume Forecast, by Application (2023-2032)

12.5.6.4. Market Revenue and Volume Forecast, by End-use (2023-2032)

Chapter 13. Company Profiles

13.1. Baxter International Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. AstraZeneca

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Aspen Pharmacare Holdings Limited

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Hikama Pharmaceuticals plc

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Abbott Laboratories

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. AbbVie Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. B. Braun Melsungen AG

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Fresenius SE & Co. KgaA

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Pfizer

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Hospira Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms